Zobrazeno 1 - 10
of 234
pro vyhledávání: '"Jihui Hao"'
Autor:
Yuexiang Liang, Guannan Sheng, Yu Guo, Yiping Zou, Hanhan Guo, Zhifei Li, Shaofei Chang, Quan Man, Song Gao, Jihui Hao
Publikováno v:
Cancer Biology & Medicine, Vol 21, Iss 5, Pp 416-432 (2024)
Objective: Tumor cell malignancy is indicated by histopathological differentiation and cell proliferation. Ki-67, an indicator of cellular proliferation, has been used for tumor grading and classification in breast cancer and neuroendocrine tumors. H
Externí odkaz:
https://doaj.org/article/cc3b41a61730440d859901ac92a3ddfd
Autor:
Ying Chang, Yao Zhou, Junrui Zhou, Wen Li, Jiasong Cao, Yaqing Jing, Shan Zhang, Yongmei Shen, Qimei Lin, Xutong Fan, Hongxi Yang, Xiaobao Dong, Shijie Zhang, Xianfu Yi, Ling Shuai, Lei Shi, Zhe Liu, Jie Yang, Xin Ma, Jihui Hao, Kexin Chen, Mulin Jun Li, Feng Wang, Dandan Huang
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Abstract Telomere length (TL) shortening is a pivotal indicator of biological aging and is associated with many human diseases. The genetic determinates of human TL have been widely investigated, however, most existing studies were conducted based on
Externí odkaz:
https://doaj.org/article/cc2719ec56f94fb89af73e6da3a3b4ad
Publikováno v:
Journal of Pancreatology, Vol 6, Iss 4, Pp 158-168 (2023)
Pancreatic ductal adenocarcinoma (PDAC) is the leading cause of cancer-related death worldwide. As PDAC is more common in older adults and the population is aging, the incidence of pancreatic adenocarcinoma is expected to increase in the coming years
Externí odkaz:
https://doaj.org/article/337ca4b6caed4567b8154ff2db16d44c
Autor:
Wenming Wu, Shouwang Cai, Rufu Chen, Deliang Fu, Chunlin Ge, Chunyi Hao, Jihui Hao, Heguang Huang, Zhixiang Jian, Gang Jin, Fei Li, Haimin Li, Shengping Li, Weiqin Li, Yixiong Li, Tingbo Liang, Xubao Liu, Wenhui Lou, Yi Miao, Yiping Mou, Chenghong Peng, Renyi Qin, Chenghao Shao, Bei Sun, Guang Tan, Huaizhi Wang, Lei Wang, Wei Wang, Weilin Wang, Junmin Wei, Heshui Wu, Zheng Wu, Changqing Yan, Yinmo Yang, Xiaoyu Yin, Xianjun Yu, Chunhui Yuan, Yupei Zhao
Publikováno v:
Journal of Pancreatology, Vol 6, Iss 3, Pp 87-95 (2023)
In clinical practice, pancreatic neuroendocrine neoplasms (pNENs) with a diameter smaller than 2 cm are commonly referred to as small pNENs. Due to their generally favorable biological characteristics, the diagnosis and treatment of small pNENs diffe
Externí odkaz:
https://doaj.org/article/acbbd6080fcf46d3a1bcdeca0468b612
Autor:
Chunhua She, Chao Wu, Weihua Guo, Yongjie Xie, Shouyi Li, Weishuai Liu, Chao Xu, Hui Li, Pei Cao, Yanfang Yang, Xiuchao Wang, Antao Chang, Yukuan Feng, Jihui Hao
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-22 (2023)
Abstract Background Gemcitabine (GEM)-based chemotherapy is the first-line option for pancreatic ductal adenocarcinoma (PDAC). However, the development of drug resistance limits its efficacy, and the specific mechanisms remain largely unknown. RUNX1,
Externí odkaz:
https://doaj.org/article/35cb9655f284424ab326102f407ef4cd
Autor:
Danqi Fu, Jingrui Yan, Zhaoyu Zhang, Yang Liu, Xiaoqing Ma, Jinsheng Ding, Shengyu Yang, Ran Zhao, Antao Chang, Chuntao Gao, Jing Liu, Tiansuo Zhao, Xiuchao Wang, Chongbiao Huang, Song Gao, Ying Ma, Bo Tang, Yukuan Feng, Hongwei Wang, Jihui Hao
Publikováno v:
Cancer Biology & Medicine, Vol 20, Iss 8, Pp 599-626 (2023)
Objective: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant gastrointestinal cancer with a 5-year survival rate of only 9%. Of PDAC patients, 15%-20% are eligible for radical surgery. Gemcitabine is an important chemotherapeutic agent fo
Externí odkaz:
https://doaj.org/article/a41f4acb910649a6b6434c404baaece3
Publikováno v:
Cancer Biology & Medicine, Vol 20, Iss 7, Pp 483-489 (2023)
Externí odkaz:
https://doaj.org/article/5fa643fccee24c04ad9c07d37b5f6d2d
Autor:
Chongbiao Huang, Hui Li, Yang Xu, Chao Xu, Huizhi Sun, Zengxun Li, Yi Ge, Hongwei Wang, Tiansuo Zhao, Song Gao, Xiuchao Wang, Shengyu Yang, Peiqing Sun, Zhe Liu, Jing Liu, Antao Chang, Jihui Hao
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 8, Iss 1, Pp 1-12 (2023)
Abstract VEGF inhibitors are one of the most successful antiangiogenic drugs in the treatment of many solid tumors. Nevertheless, pancreatic adenocarcinoma (PAAD) cells can reinstate tumor angiogenesis via activation of VEGF-independent pathways, the
Externí odkaz:
https://doaj.org/article/f0971ada20564ff1aea7a8a80808159a
Autor:
Tianxing Zhou, Yongjie Xie, Xupeng Hou, Weiwei Bai, Xueyang Li, Ziyun Liu, Quan Man, Jingyan Sun, Danqi Fu, Jingrui Yan, Zhaoyu Zhang, Yifei Wang, Hongwei Wang, Wenna Jiang, Song Gao, Tiansuo Zhao, Antao Chang, Xiuchao Wang, Hongxia Sun, Xiufeng Zhang, Shengyu Yang, Chongbiao Huang, Jihui Hao, Jing Liu
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 42, Iss 1, Pp 1-27 (2023)
Abstract Background Chemoresistance is the main reason for the poor prognosis of pancreatic ductal adenocarcinoma (PDAC). Thus, there is an urgent need to screen out new targets and compounds to reverse chemotherapeutic resistance. Methods We establi
Externí odkaz:
https://doaj.org/article/e32ae4b592a7470e8dd8678ad54192c9
Autor:
Tianxing Zhou, Quan Man, Xueyang Li, Yongjie Xie, Xupeng Hou, Hailong Wang, Jingrui Yan, Xueqing Wei, Weiwei Bai, Ziyun Liu, Jing Liu, Jihui Hao
Publikováno v:
Cancer Biology & Medicine, Vol 20, Iss 3, Pp 196-217 (2023)
Objective: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy. CD8+ T cells, cancer stem cells (CSCs), and tumor budding (TB) have been significantly correlated with the outcome of patients with PDAC, but the correlations have been i
Externí odkaz:
https://doaj.org/article/d6a9e7f1a8244667bb00cdc100d2c6c3